Banerjee Surojit, Banerjee Debadri, Singh Anupama, Saharan Vikas Anand
School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Balawala, Dehradun, 248001, Uttarakhand, India.
AAPS PharmSciTech. 2022 Mar 21;23(4):95. doi: 10.1208/s12249-022-02247-3.
COVID-19 caused by coronavirus SARS-CoV-2 became a serious threat to humankind for the past couple of years. The development of vaccine and its immediate application might be the only to escape from the grasp of this demoniac pandemic. Approximately 343 clinical trials on COVID-19 vaccines are ongoing currently, and almost all countries are motivating ongoing researches at warp speed for the development of vaccines against COVID-19. This review explores the progress in the development of the vaccines, their current status of ongoing clinical research, mechanisms, and regulatory approvals. Many pharmaceutical companies are already in the endgame for manufacturing various vaccines of which some are already being marketed across the globe, while others are yet to get approval for marketing. The primary aim of this review is to compare regulatory accepted vaccines in terms of their composition, doses, regulatory status, and efficacy. The study is conducted by grouping into approved and unapproved vaccines for marketing. Different routes of administration of vaccines along with the efficacy of the routes are also presented in the review. A wide range of database and clinical trial data is reviewed for sorting out the information on different vaccines. Unfortunately, many mutations (alpha, beta, gamma, delta, kappa, omicron etc.) of SARS-CoV-2 have attacked people in very short time, which is the great challenge for investigational vaccines. Moreover, some vaccines like Pfizer's BNT162, Oxford's ChAdOx1, Moderna's mRNA-1273, and Bharat Biotech's Covaxin have got regulatory approval in some countries for its distribution which may prove to stand tall against the pandemic.
在过去几年里,由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)对人类构成了严重威胁。疫苗的研发及其立即应用可能是摆脱这场恶魔般大流行的唯一途径。目前大约有343项关于COVID-19疫苗的临床试验正在进行,几乎所有国家都在以极快的速度推动正在进行的研究,以开发针对COVID-19的疫苗。本综述探讨了疫苗研发的进展、其正在进行的临床研究的现状、机制和监管批准情况。许多制药公司已经处于生产各种疫苗的最后阶段,其中一些已经在全球上市,而另一些尚未获得上市批准。本综述的主要目的是比较已获监管批准的疫苗在成分、剂量、监管状态和疗效方面的情况。该研究通过将疫苗分为已批准和未批准上市的疫苗进行。综述中还介绍了疫苗的不同给药途径以及这些途径的疗效。为了梳理不同疫苗的信息,对广泛的数据库和临床试验数据进行了审查。不幸的是,SARS-CoV-2的许多突变(阿尔法、贝塔、伽马、德尔塔、卡帕、奥密克戎等)在很短的时间内就侵袭了人们,这对研究中的疫苗来说是巨大的挑战。此外,一些疫苗,如辉瑞的BNT162、牛津大学的ChAdOx1、莫德纳的mRNA-1273和印度巴拉特生物技术公司的Covaxin,已在一些国家获得监管批准用于分发,这可能证明它们能够有效应对大流行。